Acadian Increases Stake in Aclaris Therapeutics, Inc. (ACRS) as Phase 2a Data Gains Spotlight
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is among the best fundamentally strong penny stocks to buy right now.
Aclaris Therapeutics Inc. (ACRS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Leucadia National Ian Cumming And Joseph Steinberg | 11,000 | $41,250 | -1% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.25 | 666,666 | $1,499,998.50 | 710,030 | 2024-11-19 | Filing | |
| $1.24 | 206,025 | $256,356.91 | 14,250,000 | 2024-08-05 | Filing | |
| $1.29 | 167,544 | $216,399.83 | 14,043,975 | 2024-08-02 | Filing | |
| $1.33 | 100,000 | $132,640.00 | 13,876,421 | 2024-07-31 | Filing | |
| $1.30 | 173,730 | $226,370.19 | 13,776,421 | 2024-07-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.53 | 300,000 | $1,359,000.00 | 13,950,000 | 2026-04-23 | Filing | |
| $5.08 | 6,000 | $30,460.20 | 129,724 | 2023-10-23 | Filing | |
| $7.32 | 6,000 | $43,894.80 | 135,724 | 2023-08-21 | Filing | |
| $10.28 | 6,000 | $61,662.60 | 141,724 | 2023-06-20 | Filing | |
| $12.63 | 30,240 | $382,070.30 | 1,273,202 | 2023-03-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,250,000 | $53,437,500 | 34.31% | |
| 2. | 5,167,469 | $19,378,009 | 0% | |
| 3. | 1,656,066 | $6,210,248 | 0% | |
| 4. | 997,850 | $3,741,938 | 0% | |
| 5. | 947,162 | $3,551,858 | 2.72% |
News See All
12 Best Fundamentally Strong Penny Stocks to Buy Right Now
Penny stock, as the name suggests, is a company’s share that is trading at a very low price, typically under $5. History has shown time and again that these stocks have performed quite well.
Aclaris Therapeutics Reports Positive Phase 2a Clinical Trial Results for ATI-2138
Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the most promising penny stocks under $5.
13 Most Promising Penny Stocks Under $5
On August 12, Jill Carey Hall, BofA Securities head of US small and mid-cap strategy, joined 'The Exchange' on CNBC to discuss the outlook for small caps, amidst their underperformance.
Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases
Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the best low priced pharma stocks to buy now.
13 Best Low Priced Pharma Stocks to Buy Now
On July 9, Afsaneh Beschloss, RockCreek Group founder & CEO, joined 'Closing Bell Overtime' on CNBC to talk about the latest round of tariff threats.
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript
Aclaris Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.23835, expectations were $-0.28. Aclaris Therapeutics, Inc.
5 Cheap Small-Cap Stocks to Buy Before the Next Breakout
In this piece, we will take a look at five cheap small cap stocks to buy before the next breakout.
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to Aclaris Therapeutics First Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode.
Did Hedge Funds Catch A Break With Aclaris Therapeutics, Inc. (ACRS)?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC.
Hedge Fund Resource Center